胃泌素释放肽DNA疫苗抑制EMT6乳腺癌生长的实验研究

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (5): 512-515.

胃泌素释放肽DNA疫苗抑制EMT6乳腺癌生长的实验研究

欧阳可栋¹, 过为¹, 吴国君¹, 张舒亚², 刘景晶¹

¹中国药科大学生命科学与技术学院,南京 210009,江苏;
²上海出入境检验检疫局,上海 200135

收稿日期:2007-03-06 修回日期:2007-04-27 发布日期:2020-10-29
通讯作者: 刘景晶,男,博导,研究方向:基因工程药学。Tel:025-83271242 E-mail:minigene1@yahoo.com.cn
作者简介:欧阳可栋,男,博士,研究方向:肿瘤免疫。Tel:13818725338 E-mail:ouyangkedong@yahoo.com.cn
基金资助:
国家自然科学基金资助( 30270298)

Suppressing effect of gastrin-releasing peptide DNA vaccine on EMT6 breast cancer growth

OUYANG Ke-dong¹, GUO Wei¹, WU Guo-jun¹, ZHANG Shu-ya², LIU Jing-jing¹

¹School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China;
²Shanghai Entry-Exit Inspection and Quarantine Bureau, Shanghai 200135, China

Received:2007-03-06 Revised:2007-04-27 Published:2020-10-29

摘要/Abstract

摘要： 目的: 观察胃泌素释放肽(GRP)DNA 疫苗对EMT6 小鼠乳腺癌生长的抑制作用。方法: 将构建的GRP DNA疫苗pCR3.1-VS-HSP65-TP-GRP6-M2 肌肉注射免疫BALB/c 雌性小鼠,2 周1 次,共5 次。采用ELISA 法对小鼠的血清中抗GRP-IgG 类抗体进行检测。最后一次免疫后第2 周,接种EMT6小鼠乳腺癌细胞。于肿瘤细胞接种后d 14,处死全部动物,称量肿瘤的质量和测量肿瘤的体积。并对瘤组织进行常规HE 染色。结果: pCR3.1-VS-HSP65-TPGRP6-M2 免疫BALB/c 小鼠,可诱导抗GRP-IgG 类抗体的产生。并对随后的EMT6 肿瘤细胞攻击有显著的抑制作用(P<0.01),抑瘤率为46.53 %。病理学检查结果显示,GRP DNA 疫苗成功地激发了宿主的抗肿瘤免疫反应;与pCR3.1-VS-HSP65-TP 对照组相比,GRP DNA疫苗免疫组小鼠EMT6肿瘤组织浸润性下降。结论: GRP DNA 疫苗显著抑制EMT6 乳腺癌生长, 为此类疫苗应用研究奠定了基础。

关键词: 胃泌素释放肽, DNA疫苗, 乳腺癌, 抑瘤率

Abstract: AIM: To observe the inhibiting effect of the GRP DNA vaccine on EMT6 breast cancer tissue. METHODS: Female BALB c mice were immunized intramuscularly with GRP DNA vaccine pCR3. 1-VS-HSP65- TP-GRP6-M2 5 times at 2-weekly intervals. The specific anti-GRP antibody was detected by ELISA method. Two weeks after the last immunization, tumor challenge experiments were performed by using EMT6. After 14 d of challenge experiments, all mice were killed and tumors were weighted. Histological analysis of tumor tissue was carried out with HE staining. RESULTS: The specific anti-GRP antibodies were detected in the antiserum of the female BALB c mice immunized with pCR3. 1-VS-HSP65-TPGRP6- M2 DNA vaccine. It showed that EMT6 tumor growth in mice of GRP DNA vaccine group was obviously suppressed (P<0.01) compared with that in pCR3. 1- VS-HSP65-TP or saline control group, with tumor inhibitory rate of 46. 53 %. Histological analysis showed that GRP DNA vaccine successfully induced anti-tumor immune responses in vivo, and, the invasiveness of EMT6 tumor tissues was markedly decreased in mice of GRP DNA vaccine group compared with that in pCR3. 1-VSHSP65- TP control group. CONCLUSION: GRP DNA vaccine can significantly suppress the growth of EMT6 breast cancer in vivo, which lays a basis for further research.

Key words: gastrin-releasing peptide, DNA vaccine, breast cancer, tumor inhibitory rate

中图分类号:

R737.9

欧阳可栋, 过为, 吴国君, 张舒亚, 刘景晶. 胃泌素释放肽DNA疫苗抑制EMT6乳腺癌生长的实验研究[J]. 中国临床药理学与治疗学, 2007, 12(5): 512-515.

OUYANG Ke-dong, GUO Wei, WU Guo-jun, ZHANG Shu-ya, LIU Jing-jing. Suppressing effect of gastrin-releasing peptide DNA vaccine on EMT6 breast cancer growth[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 512-515.

参考文献

1 Patel O, Shulkes A, Baldwin GS.Gastrin-releasing peptide and cancer[J].Biochim Biophys Acta, 2006;1766:23-41.
2 Heasley LE.Autocrine and paracrine signaling through neuropeptide receptors in human cancer[J].Oncogene, 2001;20:1563-1569.
3 Lango MN, Dyer KF, Lui VW, et al.Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck[J].J Natl Cancer Inst, 2002;94:375-383.
4 Martinez A, Zudaire E, JulianM, et al.Gastrin-releasing peptide( GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo[J].Oncogene,2005 ;24:4106-4113.
5 Markwalder R, Reubi JC.Gastrin-releasing peptide receptors in the human prostate:relation to neoplastic transformation[J].Cancer Res, 1999;59:1152-1159.
6 Zhou J, Chen J, Mokotoff M, et al.Targeting gastrin-releasing peptide receptors for cancer treatment[J].Anticancer Drugs,2004;15:921-927.
7 Smith CJ, Volkert WA, Hoffman TJ.Gastrin releasing peptide ( GRP) receptor targeted radiopharmaceuticals:a concise update[J].NuclMed Biol, 2003 ;30:861-868.
8 Kelley MJ, Linnoila RI, Avis IL, et al.Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer[J].Chest, 1997;112:256-261.
9 Papac DI, Hoyes J, Tomer KB.Epitope mapping of the gastrinreleasing peptide anti-bombesin monoclonal antibody complex by proteolysis followed by matrix-assisted laser desorption ionization mass spectrometry[J].Protein Sci, 1994;3:1485-1492.
10 金亮, 王宇, 朱爱华, 等.鼻粘膜免疫融合蛋白Hsp65-6 ×p277 预防NOD 小鼠1 型糖尿病的发生[J].中国临床药理学与治疗学, 2006;11:857-862.
11 Lui VW, Thomas SM, Zhang Q, et al.Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor[J].Oncogene, 2003 ;22:6183-6193.
12 Xiao D, Qu X, Weber HC.Activation of extracellular signalregulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells[J].Cell Signal, 2003;15:945-953.
13 姜红, 段蓉.单克隆抗体治疗肿瘤的研究进展[J].中国医院药学杂志, 2006 ;26:1407-1409.
14 Gilliam AD, Watson SA.G17DT:an antigastrin immunogen for the treatment of gastrointestinal malignancy [J].Expert Opin Biol Ther, 2007;7:397-404.
15 Halmos G, Wittliff JL, Schally AV.Characterization of bombesin gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression[J].Cancer Res, 1995;55:280-287.
16 Gugger M, Reubi JC.Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast[J].Am J Pathol, 1999;155:2067-2076.
17 Szepeshazi K, Schally AV, Halmos G, et al.Growth inhibition of estrogen-dependent and estrogen-independentMXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095[J].J Natl Cancer Inst, 1992;84:1915-1922.
18 Miyazaki M, Lamharzi N, Schally AV, et al.Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin gastrin-releasing peptide ( GRP) antagonists RC-3940-II and RC-3095[J].Eur J Cancer, 1998;34:710-717.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[9]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[10]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[11]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[12]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.
[13]	徐国防, 张思森, 刘平, 梅家转, 刘玮玮, 刘亚欧, 齐琦. 卡培他滨在中国乳腺癌患者中的群体药代动力学研究[J]. 中国临床药理学与治疗学, 2021, 26(5): 552-559.
[14]	孙红, 侯佳林, 蔡加琴, 魏晓霞, 庄捷. SUMO E3连接酶介导雄激素受体的转录促进乳腺癌他莫昔芬耐药[J]. 中国临床药理学与治疗学, 2021, 26(3): 285-291.
[15]	金乐, 蒋多晨, 陈洪晓, 刘苏, 陈昭琳, 居靖. 槲皮素通过GAS5调控GSK-3β/β-catenin逆转乳腺癌阿霉素耐药[J]. 中国临床药理学与治疗学, 2021, 26(12): 1344-1351.